The literature shows that Nrf2 agonists can regulate the expression of the downstream product HO-1 protein by activating the Nrf2 pathway and then up-regulate the activities of antioxidant proteases to remove excess ROS and reduce oxidative stress damage and further affect the liver lipid metabolism and inflammatory response to avoid liver damage and prevent the occurrence of NASH [49]. This evidence concerns the gene HMOX1 and metabolic dysfunction-associated steatohepatitis.